Test Price
1,200 AED✅ Home Collection Available
BCR-ABL Minor (p190) Quantitative PCR Test in UAE | 1,200 AED | DHA-Regulated Molecular Oncology
Executive Summary & Core Metrics
This quantitative real-time PCR assay delivers a diagnostic sensitivity of ≤0.001% for minimal residual disease monitoring in Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL). The test is performed under ISO 9001:2015 accreditation at Premises 105, Floor 1, Building 33, Dubai Healthcare City. Results are available via phone within 24 hours and via secure email within 36 hours. VIP mobile phlebotomy with temperature‑controlled cold‑chain home collection is available daily from 8 AM to 11 PM.
Test Overview & Methodology
The BCR-ABL Minor (p190) Quantitative PCR Test specifically measures the p190 BCR-ABL1 fusion transcript (e1a2) using a validated TaqMan‑based real‑time PCR platform. The assay covers a 6‑log dynamic range, enabling detection of MRD down to 0.001% (molecular remission threshold). This method is endorsed by international leukemia guidelines and is essential for guiding tyrosine kinase inhibitor therapy and predicting relapse.
| Feature | Our Test (DHA-Approved) | Standard Regional Lab |
|---|---|---|
| Methodology | ISO‑accredited Quantitative Real‑Time PCR (qPCR) with 6‑log dynamic range | Basic qPCR, often 4‑log range |
| Analytical Sensitivity | ≤ 0.001% (molecular remission threshold) | ≥ 0.01% |
| Turnaround Time | 24 h phone notification, 36 h email report | 72 h+ |
| Regulatory Compliance | DHA/MOHAP, UAE PDPL, ISO 9001:2015 | Variable |
| Home Collection | Included (8 AM–11 PM, cold‑chain) | Not typically offered |
Physician Insight & Safety Protocols
Precise molecular quantification is the cornerstone of modern leukemia management. This qPCR assay provides the sensitivity needed to detect residual disease that may escape conventional morphology. However, results must always be interpreted in the context of the patient’s full clinical and cytogenetic profile. I support your oncology team with expert correlation of these molecular signals.
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Medication Advisory
⚠ Important Medication Warning
Do not discontinue prescribed tyrosine kinase inhibitors, chemotherapy, or any other medication without consulting your treating physician. Stopping treatment prematurely can lead to disease relapse.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria
- Recent blood transfusion within 24 hours
- Hematopoietic growth factor therapy within 48 hours
- Active uncontrolled infection or systemic inflammation
Emergency Red Flags
- Sudden fever >38.5°C
- Severe bone pain or unexplained bruising
- Spontaneous bleeding (e.g., epistaxis, gingival hemorrhage)
- Signs of tumor lysis syndrome (oliguria, palpitations, muscle cramps) – seek immediate emergency care.
Patient FAQ & Clinical Guidance
1. What is the BCR-ABL Minor Quantitative Test used for?
This molecular test detects and quantifies the p190 BCR-ABL1 fusion transcript in peripheral blood, allowing precise monitoring of minimal residual disease in patients with Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL). It helps assess treatment response and detect early relapse.
2. How should I prepare for the blood draw?
No fasting is required. Please bring a signed consent form, your medical history summary, and a list of current medications. Avoid strenuous exercise for 12 hours before collection. If home phlebotomy is scheduled, our nurse will confirm the time and ensure cold‑chain transport.
3. When will I receive my results?
You will receive a telephone notification within 24 hours of sample collection, followed by a secure email report within 36 hours. The report includes the quantitative result along with interpretation guidance.
4. Can this test be performed on other sample types (e.g., bone marrow)?
While our standard validation is for peripheral blood, the same PCR protocol can be applied to bone marrow aspirate if collected at an accredited hospital. Please discuss with your oncologist to determine the optimal specimen for your clinical situation.
UAE Regulatory & Data Privacy Adherence
All molecular diagnostic activities at DNA Labs UAE comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient clinical data and genetic information are stored using encrypted, access‑controlled systems. Sample handling follows DHA‑mandated biosafety and cold‑chain protocols. For any privacy concerns, contact our data protection officer at compliance@dnalabsuae.com.
Clinical & Logistical Metadata
| Test Name | BCR-ABL Minor (p190) Quantitative PCR |
| Price (AED) | 1,200 AED |
| Turnaround Time | 24–36 hours |
| Sample Type / Matrix | Peripheral whole blood (EDTA) |
| Methodology Used | Quantitative Real‑Time PCR (TaqMan) – 6‑log dynamic range |
| ICD-10-CM Code | C91.00 (Acute lymphoblastic leukemia, not having achieved remission) |
| LOINC Code | 69403-6 (BCR/ABL1 rearrangement p190 (minor) detectable in Blood by FISH or PCR) |
| DHA Facility License & Address | License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians